Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Фармкомпании могут получать деньги только за эффективные препараты. Об этом сообщает РБК со ссылкой на копию распоряжения вице-премьера Игоря Шувалова. Шувалов...
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
Alnylam Pharmaceuticals, Inc. (ALNY) announced that Genzyme, the specialty care global business unit of Sanofi (SNY), has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.
Alnylam (ALNY) reported a loss of $1.21 per share in the third quarter of 2016 on revenues of $13.7 million.
Sanofi (SNY) reported third-quarter 2016 business earnings of $1.00 per American Depositary Share, which beat the Zacks Consensus Estimate of 86 cents by 16.28%.
BioMarin Pharmaceutical (BMRN) reported a loss of 18 cents per share in the third quarter of 2016, narrower than the year-ago loss of 44 cents.
Alnylam Pharmaceuticals, Inc. (ALNY) announced positive interim results from an ongoing phase I study, evaluating its pipeline candidate, ALN-AS1.
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
Ionis Pharmaceuticals (IONS) reported a wider-than-expected first-quarter 2016 loss of 52 cents; revenues plunged year over year.
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
BioMarin (BMRN) reported a loss of 35 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimates of a loss of 85 cents.